Objective: To evaluate the therapeutic efficacy of injecting highly agglutinative staphylococcin (HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion. Methods: 81 patients were randomized into two groups: 45 in the experimental group (HASL and Cisplatin) and 36 in the control group (Cisplatin). At first pericardial effusion was drained out from a intrapericardial catheter and then different drugs were infused, respectively. 24 h after perfusion the draining continued again until drainage quantity was less than 30 mL every day. The draining lasted 10–15 days. Results: The response rate was 91.1% for the experimental group and 80.6% for the control group. There was no significant difference between the two groups (P>0.05). The complete remission was 77.8% for the experimental group and 52.8% for the control group, which was statistically significant difference (P<0.05). The adverse effects were myelosuppression and nausea and vomiting, which were 35.6% and 40.0% in the experimental group and 72.2% and 66.7% in the control group, respectively (P<0.01, P<0.05). Conclusion: Inject- ing HASL and cisplatin into pericardial cavity may be a better way to control pericardial effusion of lung cancer. Objective: To evaluate the therapeutic efficacy of injecting highly agglutinative staphylococcin (HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion. Methods: 81 patients were randomized into two groups: 45 in the experimental group (HASL and Cisplatin) and 36 in the control group (Cisplatin). At first pericardial effusion was drained out from an intrapericardial catheter and then different drugs were infused, respectively. 24 h after perfusion the draining continued again until drainage quantity was less than 30 mL every day. The draining lasted Results were: The response rate was 91.1% for the experimental group and 80.6% for the control group. There was no significant difference between the two groups (P> 0.05). The complete remission was 77.8% for the experimental group and 52.8% for the control group, which was statistically significant difference (P <0.05). The adverse effects were myelosuppression and nausea and vomiting, which we re 35.6% and 40.0% in the experimental group and 72.2% and 66.7% in the control group, respectively (P <0.01, P <0.05). Conclusion: Injecting HASL and cisplatin into pericardial cavity may be a better way to control pericardial effusion of lung cancer.